Picture of Dermapharm Holding SE logo

DMP Dermapharm Holding SE Income Statement

0.000.00%
de flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Annual income statement for Dermapharm Holding SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue5727017949431,025
Cost of Revenue
Gross Profit300384463621661
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses465581657644781
Operating Profit108120137298244
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes104110125293216
Provision for Income Taxes
Net Income After Taxes75.277.885.9209133
Minority Interest
Net Income Before Extraordinary Items
Net Income75.377.285.8210134
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income75.377.285.8210134
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS1.541.571.864.193.27